Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre‐treated with newer P2Y12 inhibitors

OBJECTIVES: We sought to investigate the safety and potential benefit of administrating glycoprotein IIb‐IIIa inhibitors (GPIs) on top of more potent P2Y12 inhibitors. BACKGROUND: A number of clinical trials, performed at a time when pretreatment and potent platelet inhibition was not part of routin...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanchart, Katrien, Heudel, Thibaut, Ardouin, Pierre, Lemaitre, Adrien, Briet, Clément, Bignon, Mathieu, Sabatier, Rémi, Legallois, Damien, Roule, Vincent, Beygui, Farzin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364724/
https://www.ncbi.nlm.nih.gov/pubmed/34114653
http://dx.doi.org/10.1002/clc.23654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364724/
https://www.ncbi.nlm.nih.gov/pubmed/34114653
http://dx.doi.org/10.1002/clc.23654

Ejemplares similares